

1. An isolated oligonucleotide comprising a sequence of at least 8 contiguous nucleobases which is substantially identical or complementary to at least a portion of SEQ ID NO: 19, SEQ ID NO: 36 or an RNA sequence corresponding thereto.
- 5 2. The oligonucleotide of Claim 1 wherein the sequence is substantially identical or complementary to SEQ ID NO: 15 or an RNA sequence corresponding thereto.
3. The oligonucleotide of Claim 1 wherein the sequence is substantially identical or complementary to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 14, SEQ ID NO: 22,
10 SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 or an RNA sequence corresponding thereto.
4. The oligonucleotide of Claim 1 wherein the substantially identical or complementary sequence is about 10-26 nucleobases in length.
5. The oligonucleotide of Claim 1 which is an RNA oligonucleotide.
- 15 6. The oligonucleotide of Claim 1 which comprises a non-naturally occurring nucleobase, sugar or internucleotide linkage.
7. The oligonucleotide of Claim 6 which comprises a phosphorothioate internucleotide linkage.
8. A composition comprising the oligonucleotide of Claim 1 and a
20 pharmaceutically acceptable carrier, diluent or adjuvant.
9. A method for inhibiting expression of Bcl-2 comprising administering the oligonucleotide of Claim 1 to a cell, tissue or organism.
10. A method for detecting a nucleic acid encoding Bcl-2 comprising hybridizing the oligonucleotide of Claim 1 to the nucleic acid encoding Bcl-2.
- 25 11. The method of Claim 10 wherein the nucleic acid is an RNA.

12. The method of Claim 10 wherein the oligonucleotide further comprises a detectable label.

13. An isolated oligonucleotide comprising a sequence of at least 8 contiguous nucleobases which is substantially identical or complementary to at least a portion of
5 SEQ ID NO: 20, SEQ ID NO: 37 or an RNA sequence corresponding thereto.

14. The oligonucleotide of Claim 13 wherein the sequence is substantially identical or complementary to SEQ ID NO: 16 or an RNA sequence corresponding thereto.

15. The oligonucleotide of Claim 13 wherein the sequence is substantially
10 identical or complementary to SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30 or an RNA sequence corresponding thereto.

16. The oligonucleotide of Claim 13 wherein the substantially identical or complementary sequence is about 10-26 nucleobases in length.

15 17. The oligonucleotide of Claim 13 which is an RNA or DNA oligonucleotide.

18. The oligonucleotide of Claim 13 which comprises a non-naturally occurring nucleobase, sugar or internucleotide linkage.

19. The oligonucleotide of Claim 18 which comprises a phosphorothioate internucleotide linkage.

20 20. A composition comprising the oligonucleotide of Claim 13 and a pharmaceutically acceptable carrier, diluent or adjuvant.

21. A method for inhibiting expression of Bcl-2 comprising administering the oligonucleotide of Claim 13 to a cell, tissue or organism.

22. A method for detecting a nucleic acid encoding Bcl-2 comprising hybridizing
25 the oligonucleotide of Claim 13 to the nucleic acid encoding Bcl-2.

23. The method of Claim 22 wherein oligonucleotide is an RNA.

24. The method of Claim 22 wherein the oligonucleotide further comprises a detectable label.

25. An isolated oligonucleotide comprising a sequence of at least 8 contiguous nucleobases which is substantially identical or complementary to at least a portion of SEQ ID NO: 21 or an RNA sequence corresponding thereto.

26. The oligonucleotide of Claim 25 wherein the sequence is substantially identical or complementary to SEQ ID NO: 17 or an RNA sequence corresponding thereto.

27. The oligonucleotide of Claim 25 wherein the sequence is substantially identical or complementary to SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34 or an RNA sequence corresponding thereto.

28. The oligonucleotide of Claim 25 wherein the substantially identical or complementary sequence is about 10-23 nucleobases in length.

29. The oligonucleotide of Claim 25 which is an RNA oligonucleotide.

30. The oligonucleotide of Claim 25 which comprises a non-naturally occurring nucleobase, sugar or internucleotide linkage.

31. The oligonucleotide of Claim 30 which comprises a phosphorothioate internucleotide linkage.

32. A composition comprising the oligonucleotide of Claim 25 and a pharmaceutically acceptable carrier, diluent or adjuvant.

33. A method for inhibiting expression of Bcl-2 comprising administering the oligonucleotide of Claim 25 to a cell, tissue or organism.

34. A method for detecting a nucleic acid encoding Bcl-2 comprising hybridizing the oligonucleotide of Claim 25 to the nucleic acid encoding Bcl-2.

35. The method of Claim 34 wherein the nucleic acid is an RNA or DNA.

36. The method of Claim 35 wherein the oligonucleotide further comprises a detectable label.

37. A method of treating a condition susceptible to modulation of Bcl-2 expression in an organism comprising administering the composition of Claim 8 to the organism.

38. The method of Claim 37 wherein the organism is human.

39. A method of treating a condition susceptible to modulation of Bcl-2 expression in an organism comprising administering the composition of Claim 20 to the organism.

40. The method of Claim 39 wherein the organism is human.

41. A method of treating a condition susceptible to modulation of Bcl-2 expression in an organism comprising administering the composition of Claim 32 to the organism.

42. The method of Claim 41 wherein the organism is human.